atai Life Sciences (NASDAQ:ATAI, ETR:9VC) co-founder and CEO Florian Brand takes Proactive's Stephen Gunnion through the significant advancements the company made in 2023 in developing innovative mental health therapies, particularly focusing on psychedelic-based treatments for depression.
The company highlighted strategic investments and the progression of its programs, including BPL-003 R3 and ELE-101, both aimed at fitting within a two-hour in-clinic treatment window established by Spravato, an FDA-approved drug for depression. atai's DMT program, BLS-01, also aimed at short-duration psychedelic therapies, was part of this focus.
atai announced encouraging results from a Phase 2a trial of BPL-003 in treatment-resistant depression, showcasing rapid and durable antidepressant effects after a single dose. The company plans to advance this program through additional trials, including a Phase 2b study with results expected in the latter half of the year.
Besides depression, atai is exploring treatments for opioid use disorder, with a pivot to an IV formulation of Ibogaine, aiming for improved safety and efficacy.
For 2024, Atai anticipates significant milestones, including results from the COMP360 Phase 3 trial readout in the fourth quarter, marking an important development in psychedelic research. Additionally, a Phase 2b trial in cognitive impairment associated with schizophrenia is underway, testing a pro-cognitive neuromodulator, RL-007, with results expected mid-next year.